Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123
Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
Share
Why It Matters
A smart analyst thinks Abbott Laboratories is doing well. They raised their price guess by a tiny bit, from 121 to 123 dollars.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.